Patents by Inventor Ki-Hwan Chang
Ki-Hwan Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10444246Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.Type: GrantFiled: September 30, 2015Date of Patent: October 15, 2019Assignee: GREEN CROSS CORPORATIONInventors: Yong Won Shin, Juho Lee, Jeong-Ae Lim, Ki Hwan Chang, Min-Soo Kim
-
Publication number: 20190153117Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: January 28, 2019Publication date: May 23, 2019Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Se-Ho Kim, Kwang-Won Hong, Ki-Hwan Chang, Min-Soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
-
Publication number: 20170307630Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.Type: ApplicationFiled: September 30, 2015Publication date: October 26, 2017Applicant: GREEN CROSS CORPORATIONInventors: Yong Won SHIN, Juho LEE, Jeong-Ae LIM, Ki Hwan CHANG, Min-Soo KIM
-
Publication number: 20170260257Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: ApplicationFiled: May 16, 2017Publication date: September 14, 2017Inventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Patent number: 9683029Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: GrantFiled: July 8, 2013Date of Patent: June 20, 2017Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Publication number: 20170145107Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Se-Ho KIM, Kwang-Won HONG, Ki-Hwan CHANG, Min-soo KIM, Mi-jung LEE, Jong-hwa WON, Min-Kyu HUR, Hyun-Soo CHO, Ji-Ho YOO
-
Publication number: 20160311862Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: ApplicationFiled: July 11, 2016Publication date: October 27, 2016Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho KIM, Kwang-Won HONG, Yong-Won SHIN, Ki Hwan CHANG, Min-soo KIM, Jung-Ae IM
-
Patent number: 9415100Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: GrantFiled: July 25, 2011Date of Patent: August 16, 2016Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
-
Patent number: 9200062Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: GrantFiled: May 21, 2014Date of Patent: December 1, 2015Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Publication number: 20150231220Abstract: The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: March 27, 2013Publication date: August 20, 2015Applicants: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Ki Hwan Chang, Min-soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
-
Publication number: 20150166637Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: ApplicationFiled: July 8, 2013Publication date: June 18, 2015Inventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Publication number: 20140302598Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: May 21, 2014Publication date: October 9, 2014Inventors: Se-Ho KIM, Ki Hwan CHANG, Kwang-Won HONG, Yong-Won SHIN, Min-soo KIM, Hae-Won LEE, Kyung Hwan RYOO, Dong Hyuck SEO, Jean Man KIM, Yong Nam SHIN, Sunmi KOO, Jung-Ae LIM, Mijung LEE, Yeon Kyung LEE, Misun SEO
-
Patent number: 8840895Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: GrantFiled: July 8, 2010Date of Patent: September 23, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Publication number: 20140112923Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: ApplicationFiled: July 25, 2011Publication date: April 24, 2014Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
-
Publication number: 20120264921Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: July 8, 2010Publication date: October 18, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Publication number: 20120231021Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: ApplicationFiled: November 2, 2009Publication date: September 13, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo
-
Publication number: 20100260712Abstract: The present invention provides a use of a human antibody against a hepatitis B virus (HBV) surface antigen (HBsAg). The antibody exhibits an excellent HBV neutralizing ability, and thus, is useful for the prevention or treatment of the HBV infection or a disease caused thereby.Type: ApplicationFiled: November 21, 2008Publication date: October 14, 2010Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Nam Shin, Yong-Won Shin, Ki-Hwan Chang, Kyung-Hwan Ryoo, Jin-Seol Choi, Pan-Kyung Kim, Ki-Tae Bong, Dong-Hyuck Seo, Sun-Jeong Oh